Table 2.

Patient and tumour characteristics

Characteristic	Number (%)
Age	Median: 59
	Range: [31, 82]
Sex	Male: 136 (88.9%)
	Female: 17 (11.1%)
Smoking status	Non-smoker: 68 (44.4%)
	< =10 Packs/year: 25 (16.3%)
	> 10–20 Packs/year: 18 (11.8%)
	> 20 Packs/year: 27 (17.6%)
	Unknown: 15 (9.8%)
Primary site	Tonsil: 92 (60.2%)
	Base of tongue: 55 (35.9%)
	Oropharynx: 1 (0.7%)
	Other: 5 (3.2%)
T stage 7th Ed/8th Ed	T1: 47 (30.7%)
	T2: 67 (43.8%)
	T3: 29 (19.0%)
	T4a: 9 (5.9%)
	T4b: 1 (0.7%)
N stage 7th Ed	N0: 17 (11.1%)
	N1: 27 (17.6%)
	N2a: 16 (10.5%)
	N2b: 60 (39.2%)
	N2c: 28 (18.3%)
	N3: 5 (3.3%)
N stage 8th Ed	N0: 17 (11.1%)
	N1: 103 (66.9%)
	N2: 28 (18.3%)
	N3: 5 (3.3%)
Systemic therapy	Nil: 39 (25.4%)
	Weekly Cisplatin: 85 (55.6%)
	Cetuximab: 10 (6.5%)
	Neoadjuvant TPF: 14 (9.2%)